Upgrade to SI Premium - Free Trial

Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord Genuity

November 10, 2017 7:22 AM
Canaccord Genuity raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $140.00 (from $81.00) while maintaining a Buy rating.Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Hot Comments

Next Articles